Validation of Serum Amyloid alpha as an Independent Biomarker for Progression-Free and Overall Survival in Metastatic Renal Cell Cancer Patients

JS Vermaat, FL Gerritse, AA van der Veldt, WM Roessingh, TM Niers, SF Oosting, Stefan Sleijfer, JM Roodhart, JH Beijnen, JH Schellens, JA Gietema, Eva Boven, DJ Richel, JB Haanen, EE Voest

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)


Background: We recently identified apolipoprotein A2 (ApoA2) and serum amyloid a (SAA) as independent prognosticators in metastatic renal cell carcinoma (mRCC) patients, thereby improving the accuracy of the Memorial-Sloan Kettering Cancer Center (MSKCC) model. Objective: Validate these results prospectively in a separate cohort of mRCC patients treated with tyrosine kinase inhibitors (TKIs). Design, setting, and participants: For training we used 114 interferon-treated mRCC patients (inclusion 2001-2006). For validation we studied 151 TKI-treated mRCC patients (inclusion 2003-2009). Measurements: Using Cox proportional hazards regression analysis, SAA and ApoA2 were associated with progression-free survival (PFS) and overall survival (OS). In 72 TKI-treated patients, SAA levels were analyzed longitudinally as a potential early marker for treatment effect. Results and limitations: Baseline ApoA2 and SAA levels significantly predicted PFS and OS in the training and validation cohorts. Multivariate analysis identified SAA in both separate patient sets as a robust and independent prognosticator for PFS and OS. In contrast to our previous findings, ApoA2 interacted with SAA in the validation cohort and did not contribute to a better predictive accuracy than SAA alone and was therefore excluded from further analysis. According to the tertiles of SAA le Conclusions: SAA but not ApoA2 was shown to be a robust and independent prognosticator for PFS and OS in mRCC patients. When incorporated in the MSKCC model, SAA showed additional prognostic value for patient management. (C) 2012 European Association of Urology. Published by Elsevier B. V. All rights reserved.
Original languageUndefined/Unknown
Pages (from-to)685-695
Number of pages11
JournalEuropean Urology
Issue number4
Publication statusPublished - 2012

Research programs

  • EMC MM-03-86-01
  • EMC MM-03-86-08

Cite this